News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017